Short-interval lower-dose intravenous cyclophosphamide as induction and maintenance therapy for lupus nephritis: a prospective observational study

被引:0
作者
X. W. Zhang
Chun Li
X. X. Ma
J. X. Zhao
Yuan An
Shuang Liu
Yan Li
Z. G. Li
机构
[1] Peking University People’s Hospital,Department of Rheumatology and Immunology
[2] Peking University Third Hospital,Department of Rheumatology and Immunology
来源
Clinical Rheumatology | 2014年 / 33卷
关键词
Cyclophosphamide; Lupus nephritis; Menstrual disturbance;
D O I
暂无
中图分类号
学科分类号
摘要
Cyclophosphamide (CYC) has long been considered a gold standard in inducing renal remission and preventing renal flares for patients with systemic lupus erythematosus (SLE). However, the rational use of CYC has not reached a consensus, such as the timing and length of treatment, the route of administration, and the ideal dosage. The objective of this study was to assess the efficacy and safety of short-interval lower-dose (SILD) intravenous (IV) CYC in the treatment of SLE. A total of 225 patients with lupus nephritis were randomly assigned to a 1-year trial, either the SILD group (12 fortnightly pulses at a fixed dose of 400 mg followed by 6 monthly pulses) or high-dose (HD) group (6 monthly pulses followed by two quarterly pulses at a dose of 0.5~1.0 g/m2). At 6 months of treatment, 28 % (30/107) of patients in the SILD group reached a complete remission (CR), and 51.4 % (55/107) were in partial remission (PR), as compared with 32.7 % (35/107) and 45.8 % (49/107) in the HD group, respectively. Serum albumin, 24-h urinary protein, and the scores of disease activity were significantly improved in both groups at 6 months and maintained at the end of clinical trial. However, the SILD group showed much less menstrual disturbances (11.5 %), gastrointestinal adverse effects (5.3 %), and leukopenia (9.7 %) than the HD group (28.6, 26.8, and 19.8 %, respectively) at the end of clinical trial. The efficacy of the short-interval lower-dose (SILD) IV CYC regimen in the treatment of lupus nephritis is equivalent to that of the high-dose (HD) regimen, whereas the incidence of adverse events is much lower in the SILD group.
引用
收藏
页码:939 / 945
页数:6
相关论文
共 46 条
  • [31] Optimal exposure of mycophenolic acid for induction therapy of childhood lupus nephritis patients: an observational cohort study
    Zhang, Lu
    Chen, Lizhi
    Liu, Xiaohong
    Huang, Zhijun
    Zheng, Yifan
    Tang, Kejing
    Jiang, Xiaoyun
    Chen, Pan
    [J]. RHEUMATOLOGY, 2024, 63 (SI2) : SI180 - SI187
  • [32] Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study
    Wang, H. Y.
    Cui, T. G.
    Hou, F. F.
    Ni, Z. H.
    Chen, X. M.
    Lu, F. M.
    Xu, F. F.
    Yu, X. Q.
    Zhang, F. S.
    Zhao, X. Z.
    Zhao, M. H.
    Wang, G. B.
    Qian, J. Q.
    Cai, G. Y.
    Zhu, T. Y.
    Wang, Y. H.
    Jiang, Z. P.
    Li, Y. N.
    Mei, C. L.
    Zou, W. Z.
    [J]. LUPUS, 2008, 17 (07) : 638 - 644
  • [33] Efficacy and safety of high-dose of mycophenolate mofetil compared with cyclophosphamide pulse therapy as induction therapy in Japanese patients with proliferative lupus nephritis
    Ohkubo, Naoaki
    Iwata, Shigeru
    Nakano, Kazuhisa
    Miyagawa, Ippei
    Hanami, Kentaro
    Fukuyo, Shunsuke
    Miyazaki, Yusuke
    Kawabe, Akio
    Nakayamada, Shingo
    Tanaka, Yoshiya
    [J]. MODERN RHEUMATOLOGY, 2022, 32 (06) : 1077 - 1085
  • [34] Intensified, intermittent, low-dose intravenous cyclophosphamide together with oral alternate-day steroid therapy in lupus nephritis (long-term outcome)
    Meral Calguneri
    Zeynep Ozbalkan
    M. Akif Ozturk
    Sule Apras
    A. Ihsan Ertenli
    Sedat Kiraz
    [J]. Clinical Rheumatology, 2006, 25 : 782 - 788
  • [35] Intensified, intermittent, low-dose intravenous cyclophosphamide together with oral alternate-day steroid therapy in lupus nephritis (long-term outcome)
    Calguneri, Meral
    Ozbalkan, Zeynep
    Ozturk, M. Akif
    Apras, Sule
    Ertenli, A. Ihsan
    Kiraz, Sedat
    [J]. CLINICAL RHEUMATOLOGY, 2006, 25 (06) : 782 - 788
  • [36] Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS)
    Sinclair, A.
    Appel, G.
    Dooley, M. A.
    Ginzler, E.
    Isenberg, D.
    Jayne, D.
    Wofsy, D.
    Solomons, N.
    [J]. LUPUS, 2007, 16 (12) : 972 - 980
  • [37] A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis
    Lu, F.
    Tu, Y.
    Peng, X.
    Wang, L.
    Wang, H.
    Sun, Z.
    Zheng, H.
    Hu, Z.
    [J]. LUPUS, 2008, 17 (07) : 622 - 629
  • [38] Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan
    Sakai, R.
    Kurasawa, T.
    Nishi, E.
    Kondo, T.
    Okada, Y.
    Shibata, A.
    Nishimura, K.
    Chino, K.
    Okuyama, A.
    Takei, H.
    Nagasawa, H.
    Amano, K.
    [J]. LUPUS, 2018, 27 (02) : 273 - 282
  • [39] Short-term incremental prednisone therapy in patients with serologically active clinically quiescent lupus nephritis: a retrospective observational study
    An, Ning
    Chen, Hao-tao
    Deng, Wen-bo
    Zhang, Le
    Chen, Jin-xia
    Yao, Cui-wei
    Liu, Hua-feng
    Xu, Yong-zhi
    [J]. EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2024, 29 (01) : 555
  • [40] LONG-TERM EFFICACY OF HIGH-DOSE INTRAVENOUS METHYLPREDNISOLONE PULSES IN ACTIVE LUPUS NEPHRITIS - A 21-MONTH PROSPECTIVE-STUDY
    BERTONI, M
    BRUGNOLO, F
    BERTONI, E
    SALVADORI, M
    ROMAGNANI, S
    EMMI, L
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1994, 23 (02) : 82 - 86